FRMD8

Across TCGA pan-cancer cohorts, FRMD8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FRMD8 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FRMD8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FRMD8 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where FRMD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	II,III,IV	1.000	0.897	.019	44	view →
PDAC	OS	Quartile	III,IV	1.000	0.409	.016	11	view →
CCRCC	OS	Median	All	0.891	0.995	.020	9	view →
LSCC	OS	Quartile	II,III,IV	0.633	0.901	.035	4	view →
GBM	DFS	Tertile	All	0.674	0.839	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FRMD8–HNSC (OS)

Open the HNSC breakdown →